Nivolumab plus cisplatin/pemetrexed or cisplatin/gemcitabine as induction in resectable NSCLC.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.tps8582
Abstract: TPS8582Background: For patients (pts) with stage IB (≥4cm)-IIIA Non-small-cell lung cancer (NSCLC), multi-modality therapy yields a modest improvement in 5 year post-surgical overall survival (OS),... read more here.
Keywords: cisplatin gemcitabine; gemcitabine induction; cisplatin pemetrexed; nivolumab plus ... See more keywords